Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE.
BENICAR HCT vs OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral, one tablet once daily. Starting dose: Olmesartan medoxomil 20 mg / hydrochlorothiazide 12.5 mg. Titrate up to maximum 40 mg / 25 mg daily as needed.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Olmesartan: terminal half-life ~10–15 hours; no accumulation. Hydrochlorothiazide: terminal half-life ~6–15 hours; prolonged in renal impairment.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Olmesartan: ~60% renal, ~35% fecal. Hydrochlorothiazide: ~70% renal (unchanged), ~30% biliary/fecal.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB